

WFS1 M781I — Wolframin

Methionine → Isoleucine at position 781. C-terminal ER-luminal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.660, DynaMut2 $\Delta\Delta G$ -0.72 kcal/mol (destabilising).

IDENTITY

| | |
|-------------------|-----------------------------------|
| Variant | M781I (p.Methionine781Isoleucine) |
| DNA change | c.2343G>A |
| Gene · Protein | WFS1 · Wolframin (890 aa) |
| UniProt | O76024 · WFS1_HUMAN |
| ClinVar accession | VCV001678045 |
| Amino acid change | Methionine (M) → Isoleucine (I) |

STRUCTURAL CONTEXT

| | |
|----------------------|---|
| AlphaFold model | AF-O76024-F1, v6 |
| pLDDT at residue 781 | 84.12 HIGH CONFIDENCE |
| Domain | C-terminal ER-luminal (calcium binding, calmodulin, chaperone) |
| Position context | C-terminal luminal domain · position 781 projects into the ER lumen |
| IDR flag | No — pLDDT well above 50 threshold |

Position 781 sits in the C-terminal luminal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na⁺/K⁺ ATPase β 1. The wild-type residue is hydrophobic sulfur (methionine); the mutant is medium hydrophobic (isoleucine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

0.660am_class: **likely pathogenic** — threshold > 0.564DYNAMUT2 $\Delta\Delta G$ **-0.72** kcal/mol

Destabilising · Job 178092128367

PLDDT (ALPHAFOLD)

84.12

high confidence

CLINICAL EVIDENCE

| | |
|------------------------|--|
| ClinVar classification | UNCERTAIN SIGNIFICANCE |
| Review status | criteria provided, multiple submitters, no conflicts |
| Last evaluated | 2025/10/26 00:00 |
| Inheritance | Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations. |
| WFS1 variant landscape | M781I is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar) <ul style="list-style-type: none">(no conditions catalogued) |

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G 2-4$ → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

Category 3/4 — Most Druggable

$|\Delta\Delta G|=0.72 < 2$ kcal/mol (fold intact) + AlphaMissense 0.660 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Wolframins fold survives this substitution ($|\Delta\Delta G|=0.72$ kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.660. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.